天津招聘

1.Support program office to formulate, organize and monitor inter-connected projects, including IO and combo

2.Coordinate cross-project activities and come up with program overview, which includes defining the milestones, tracking on project progress, key stakeholders’ status and feedback.

3.Support program dedicated timeline, controlling and budgeting.

4.Identify risk that impacts on program timeline, tracking and help stakeholders to perform risk and mitigation plan

5.Take the lead for program progress update meeting and collect project updates as well as stakeholders, including manufacture, regulatory affairs and medical department etc.

6.To be responsible for program document generation, collecting and archiving

Cross-Functional Collaboration

1.To inform key stakeholders of status, issues, problems, and recommended solutions as appropriate on the responsible IO-combo program

Execute on the developed communication plan to ensure timely and effective communication

Education

Master degree above (in pharmaceutical, medical or other relevant biological science)

Experience

1.Experience in scientific related field, oncology is plus

Experience in program or project management is plus

Skills

1.Ability to quickly extract key insights from an excess of data and details and effectively prioritize programs /projects based

2.Excellent skills including root cause analysis, strategic thinking, ability to frame problems and opportunities using supporting data, problem solving and measuring impact

3.Outstanding interpersonal and communication (oral and written) including Powerpoint presentations, data management and analytical skills are essential

4.Good command in written& spoken English is highly preferred

Proficient in MS Project and Office for management

    复宏汉霖（*******）是一家国际化的创新生物制药公司，旨在为全球患者提供质高价优的创新生物药，产品覆盖肿瘤、自身免疫性疾病等领域。自2010年成立以来，公司以全球联动、整合创新为产品开发理念，在中国上海、中国台北和美国加州均设有研发中心，具备了协同增效的突出优势。复宏汉霖主要的产品开发策略是仿创结合，从生物类似药起步，逐步开发创新型单抗产品，结合自主开发的抗PD-1和PD-L1单抗，在国内率先推出免疫联合疗法，前瞻性布局了一个多元化、创新单抗及肿瘤免疫联合疗法管线，打造出研究、开发、商业化生产的综合性生物医药全产业链平台。

    截至目前，复宏汉霖已有1个产品成功上市，2个产品获得中国新药上市申请受理，1个产品获得欧盟营销授权申请受理，10个产品、8个联合治疗方案在全球范围内开展20多项临床试验。其中，公司首款重磅产品汉利康？（利妥昔单抗注射液）于2019年2月获国家药监局新药上市注册批准，成为中国***获批上市的生物类似药。HLX03（阿达木单抗注射液）与HLX02（注射用曲妥珠单抗）已获国家药监局新药上市申请受理，现已纳入优先审评程序。HLX02相继在中国大陆、乌克兰、欧盟波兰和菲律宾全面启动国际多中心3期临床试验，成为国内***开展国际多中心3期临床研究的生物类似药，并于2019年6月获欧洲药品管理局营销授权申请受理。此外，公司已陆续就HLX10（抗PD-1单抗）与自有产品HLX04（贝伐珠单抗生物类似药）、HLX07（抗EGFR单抗）以及化疗联用开展多项肿瘤免疫联合疗法，在全球范围内开展多个临床研究。